Develops gene therapies and small-molecule drug candidates aimed at the underlying causes of heart disease for patients with genetic heart conditions and other cardiac, muscular and metabolic diseases.
10-K for FY2025, filed Mar 11, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 11, 2026
8-K, filed Jul 2, 2026
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to…View ↗
8-K, filed Jun 29, 2026
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) announced that Eric Hyllengren, M.B.A., will join the Company as Chief…View ↗
Narrower platform focus
The older report described separate gene therapy, cellular regeneration and precision medicine platforms, including a cardiac regeneration program. The latest report focuses its clinical-stage pipeline on gene therapies and a small-molecule candidate, and describes its discovery capabilities across modalities.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 11, 2026We are advancing a deep and diverse pipeline of therapeutic programs intended for both rare and highly prevalent forms of heart disease.…View ↗
Our distinct, but interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and suite of integrated capabilities…View ↗
Early-Stage Research Efforts: In addition to our lead product candidates, we have multiple early-stage programs progressing through…View ↗
We have established three distinct but interrelated product platforms -- Gene Therapy, Cellular Regeneration and Precision Medicine -- to…View ↗
Manufacturing approach
The older report described internal AAV manufacturing capabilities and a manufacturing center. The latest report describes process and analytical development capabilities that supported clinical trial material production and development of know-how to manage later manufacturing; a later filing says the company plans to transfer its process to a contract manufacturer.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 11, 2026 8-K, filed Jul 2, 2026Our distinct suite of integrated capabilities broadly enable modality agnostic target identification and validation, design of AAV-based…View ↗
Competes with Bristol Myers Squibb, Cytokinetics, Edgewise Therapeutics, Lexicon Pharmaceutical, Imbria Pharmaceutical, Novartis, Eli Lilly, Boehringer Ingleheim, Astra Zeneca, Italfarmaco, Catalyst Pharmaceuticals, Santhera Pharmaceutical, PTC Therapeutics, Sarepta Therapeutics, NS Pharma, Capricor Therapeutics, Avidity Bioscience, Rocket Pharmaceutical, and Lexeo Therapeutics
10-K for FY2025, filed Mar 11, 2026TN-201: We believe the principal competition for TN-201 will be programs that address the underlying genetic cause of MYBPC3-associated…View ↗
Loading...